Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2021 - 2026)

Zentalis Pharmaceuticals has reported Total Current Liabilities over the past 6 years, most recently at $35.2 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 28.72% year-over-year to $35.2 million; the TTM value through Mar 2026 reached $35.2 million, down 28.72%, while the annual FY2025 figure was $36.6 million, 30.66% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $35.2 million at Zentalis Pharmaceuticals, down from $36.6 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $69.4 million in Q4 2023 and troughed at $35.2 million in Q1 2026.
  • A 5-year average of $50.9 million and a median of $52.7 million in 2024 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: increased 29.6% in 2023 and later tumbled 41.49% in 2025.
  • Year by year, Total Current Liabilities stood at $56.6 million in 2022, then rose by 22.45% to $69.4 million in 2023, then decreased by 23.99% to $52.7 million in 2024, then plummeted by 30.66% to $36.6 million in 2025, then decreased by 3.62% to $35.2 million in 2026.
  • Business Quant data shows Total Current Liabilities for ZNTL at $35.2 million in Q1 2026, $36.6 million in Q4 2025, and $37.2 million in Q3 2025.